Clinical Trial Update: A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the dose levels, safety, and drug levels after a single intramuscular injection of KarXT in participants with schizophrenia;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Schizophrenia | Phase 1 | Status: RECRUITING